Humira for juvenile arthritis

The licence for Humira (adalimumab) has been extended to include the treatment of active polyarticular juvenile idiopathic arthritis.

Humira (adalimumab) can be used to treat juvenile arthritis in patients aged 13 to 17 years when response to one or more DMARDs has been inadequate.

Humira is also indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease and psoriasis in adults.

View Humira drug record

Further information: Abbott

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Proposed withdrawal of bipolar disorder treatment revoked

Proposed withdrawal of bipolar disorder treatment revoked

The manufacturer of first-line bipolar disorder treatment...

NICE recommends further migraine prevention option

NICE recommends further migraine prevention option

Galcanezumab (Emgality) is the second calcitonin gene-related...